← all works
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Prostate Cancer Treatment and Research
- Field
- Medicine
- Canadian institutions
- Université de MontréalBC Cancer Agency
- Funders
- Janssen Research and DevelopmentUCLH Biomedical Research Centre
- Keywords
- Abiraterone acetateMedicinePlaceboPrednisoneProstate cancerClinical endpointInterim analysisInternal medicineEnzalutamideDocetaxelPopulationOncologyAndrogen deprivation therapyClinical trialCancerAndrogen receptorPathology
- Has abstract in OpenAlex
- no